{"filing":{"accession_number":"0001193125-26-301520","cik":"0001661998","ticker":"QTTB","company_name":"Q32 Bio Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"d143274d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526301520/d143274d8k.htm"},"events":[{"id":17517,"run_id":15691,"accession_number":"0001193125-26-301520","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Q32 Bio announced topline results from Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart in alopecia areata, demonstrating robust clinical activity (35.3% mean SALT score reduction) and a favorable safety profile. This is a material clinical milestone for a development-stage biopharmaceutical company, representing progress toward potential registration and commercialization of a lead product candidate. While not a traditional earnings release or M\u0026A event, the clinical trial results constitute a material operational and strategic milestone that would affect investor assessment of the company's pipeline and commercial prospects.","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16021,"accession_number":"0001193125-26-301520","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Q32 Bio announced topline results from Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart in alopecia areata, demonstrating robust clinical activity (35.3% mean SALT score reduction) and a favorable safety profile. This is a material clinical milestone for a development-stage biopharmaceutical company, representing progress toward potential registration and commercialization of a lead product candidate. While not a traditional earnings release or M\u0026A event, the clinical trial results constitute a material operational and strategic milestone that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:40:38.598782+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16021,"accession_number":"0001193125-26-301520","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Q32 Bio announced topline results from Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart in alopecia areata, demonstrating robust clinical activity (35.3% mean SALT score reduction) and a favorable safety profile. This is a material clinical milestone for a development-stage biopharmaceutical company, representing progress toward potential registration and commercialization of a lead product candidate. While not a traditional earnings release or M\u0026A event, the clinical trial results constitute a material operational and strategic milestone that would affect investor assessment of the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T12:40:38.598782+00:00","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-07-13"}]}